535 Watson Drive
Claremont, CA 91711 Location: Building 535
Phone: (909) 607-9145
Fax: (909) 607-8086
Email: admissions[at symbol]kgi.edu
In the News: Genzyme Stocks Out
It was a serendipitous occasion when the New York Times published an article detailing the repercussions of Genzyme’s drug shortage the very same day that Matt Croughan, distinguished KGI Professor and director of the Amgen Bioprocessing Center, gave a lecture to the first year Bioseparations class on the very same topic.
Professor Croughan’s lecture that day not only elucidated the common causes and preventative measures for viral infections in bioprocessing plants, but also specifically warned of the dangers of not investing in new viral barrier systems that greatly reduce the chance of plant-wide viral contaminations and the resulting possible stock out of a vital drug. Consequences of which can range from a decline in share price to increased patient mortality, both of which are detrimental to company image. Professor Croughan’s personal perspectives from his work at Genentech provided insight into the importance of working alongside the Food and Drug Administration.
KGI strives to equip its students with real industry knowledge that they can take with them on their future endeavors whether they are in biologics manufacturing, pharmaceutical development, or clinical and regulatory affairs. Our goal is to shape informed leaders who will operate ethically in order to provide for the common welfare and improve the quality of life through works in the life sciences. Learn more about Bioprocessing at KGI and read more about Genzyme in the New York Times.
By Christina Lai (MBS '11)